- Home
- QTTB vs ATRA Comparison
QTTB vs ATRA Comparison
Compare QTTB & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QTTB | ATRA |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.3M | 38.9M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | QTTB | ATRA |
|---|---|---|
| Price | $6.37 | $4.89 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.00 | $5.00 |
| AVG Volume (30 Days) | ★ 349.4K | 229.0K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | 122.52 |
| EPS | 2.42 | ★ 2.57 |
| Revenue | $53,737,000.00 | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.64 | ★ $1.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.38 | $3.92 |
| 52 Week High | $8.05 | $19.15 |
Technical Indicators
Market Signals| Indicator | QTTB | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 46.83 |
| Support Level | $3.49 | $4.70 |
| Resistance Level | $7.80 | $5.65 |
| Average True Range (ATR) | 0.93 | 0.45 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 34.32 | 32.09 |
Price Performance
Historical ComparisonAbout QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).